Printer Friendly

BIOMERICA ANNOUNCES THE START OF CLINICAL TRIALS ON TESTS FOR PREDICTING DIABETES

          BIOMERICA ANNOUNCES THE START OF CLINICAL TRIALS
                  ON TESTS FOR PREDICTING DIABETES
    NEWPORT BEACH, Calif., Nov. 18 /PRNewswire/ -- Biomerica Inc. (NASDAQ: BMRA), has announced that it will begin clinical trials on two blood test kits for identifying individuals who are likely to develop diabetes as early as seven years before the onset of the disease.  The tests measure antibodies produced by the human body against insulin and the pancreatic islet cells which produce insulin. During the clinical phase, the kits will be marketed for research only.
    These unique kits will enable Biomerica to participate in the diabetic market totaling $22 billion per year.
    Diabetes affects 7 million Americans and another million individuals have the molecular indicators of the impending disease in their blood for months, years, or perhaps even decades before clinical symptoms appear.  The ability to detect this pre-diabetic state through Biomerica's kits may permit physicians to take preventive measures before the disease becomes incurable and causes serious injury to the eyes, kidneys, blood vessels and nervous system.
    Biomerica is a biomedical company engaged in the development, manufacturing and sales of advanced diagnostic products for heart attack, predisposition of diabetes, allergy, occult blood, certain cancers, and other clinical tests.  In addition, Biomerica has an interest in a transdermal drug delivery operation as well as an orthodontic manufacturing firm.
    -0-                      11/18/91
    /CONTACT:  Joseph H. Irani, president or Zackary S. Irani, 714-645-2111, of Biomerica/
    (BMRA) CO:  Biomerica ST:  California IN:  MTC SU: AL-EH -- LA003 -- 1247 11/18/91 09:04 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 18, 1991
Words:252
Previous Article:NINTENDO TACKLES AFTER-SCHOOL LATCHKEY ISSUE; 'CLUB MARIO' OPENS ITS DOORS AT BELLEVUE BOYS AND GIRLS CLUB
Next Article:TELETRAC 24-HOUR VEHICLE SECURITY SERVICE INTRODUCED TODAY IN DETROIT
Topics:


Related Articles
BIOMERICA ANNOUNCES NEW FINANCING FOR LANCER ORTHODONTICS
BIOMERICA SIGNS AN AGREEMENT WITH SAV-ON/OSCO FOR DISTRIBUTION OF STOOL BLOOD TEST KIT
BIOMERICA'S ULCER TEST APPROVED IN JAPAN
BIOMERICA'S ULCER TEST APPROVED IN JAPAN
Biomerica Announces New Patent for the Technology it is Using to Develop Tests for Ulcers and Stomach Cancer
Biomerica Receives New Patent for Test to Predict Diabetes Years Before Onset
Biomerica to Produce Diagnostic Products For Worldwide Distribution by ICN Pharmaceuticals.
Neurocrine Biosciences and Taisho Pharmaceutical Initiate A Pivotal Phase IIb Clinical Trial for NBI-6024, A Therapeutic Vaccine for the Treatment of...
Biomerica Launches New Diabetes Diagnostic Test.
Biodel receives notice of issuance for United States patent covering lead product candidates.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters